Summer Student Placement Underway at Amprologix
14 August 2025This summer we’ve been pleased to welcome Rutendo Mupfumi from the University of Plymouth to the Amprologix lab. As part…
This summer we’ve been pleased to welcome Rutendo Mupfumi from the University of Plymouth to the Amprologix lab. As part…
Amprologix joins a global network of innovators We're proud to announce that Amprologix is one of the 103 finalists selected…
Mat Upton, CSO, presented the latest results from ongoing research at ESCMID Global 2025. ESCMID Global 2025 - the Congress of…
Mat Upton, CSO, presented new data at the 9th AMR conference in Basel on 25th February. It was suggested that…
Amprologix will be attending the Investival Showcase in London on 18th November 2024 Amprologix will be attending the Investival Showcase in…
Amprologix joins a global network of innovators We're proud to announce that Amprologix is one of the 103 finalists selected to participate in the MassChallenge Switzerland & UK Accelerator Programme 2025, chosen from a pool of 1,527 high-potential startups worldwide. This milestone places Amprologix among a global community of science-driven innovators who are committed to […]
Mat Upton, CSO, presented the latest results from ongoing research at ESCMID Global 2025. ESCMID Global 2025 - the Congress of the European Society of Clinical Microbiology and Infectious Diseases - ran from April 11-15 in Vienna, and was attended by an audience of leading experts in infectious diseases and clinical microbiology. Amprologix presented results from […]
Mat Upton, CSO, presented new data at the 9th AMR conference in Basel on 25th February. It was suggested that probably half the global antimicrobial R&D activity was represented by attendees in the room. In a recent robust skin infection model with MRSA strain USA300, data demonstrate that a single daily dose of lead antibiotic […]
Amprologix will be attending the Investival Showcase in London on 18th November 2024 Amprologix will be attending the Investival Showcase in London on 18th November 2024. We look forward to meeting industry partners and investors who share our passion for developing new treatments to combat the rising global threat from antimicrobial resistance, including superbugs like MRSA and VRE. For […]
